Immunosuppressed patients outside of the US should have access to the monoclonal antibody Bebtelovimab, the only therapeutic antibody efficient against the BA.5 Omicron variant currently dominant in most European countries, says Prof. Michel Goldman from the Royal Belgian Academy of Medicine, I3Health, Free University of Brussels, and FEAM representative on the HERA Civil Society Advisory Forum. He calls for HERA to consider the urgent replication at European level of the recent FDA emergency use authorization that will soon enable US physicians to administer the neutralizing monoclonal antibody. Read his Letter of 5 August 2022 in the Financial Times here accessible on LinkedIn.
